Overview

Sonazoid-Enhanced Ultrasound in Detecting Sentinel Lymph Node in Patients With Cutaneous Melanoma

Status:
Terminated
Trial end date:
2020-01-09
Target enrollment:
Participant gender:
Summary
This pilot phase I trial studies how well sonazoid-enhanced ultrasound works in detecting sentinel lymph node in patients with cutaneous melanoma. Sonazoid is a contrast agent that may make it easier to see if the tumor cells have spread to the sentinel lymph node using an ultrasound.
Phase:
Phase 1
Details
Lead Sponsor:
University of Southern California
Collaborator:
National Cancer Institute (NCI)